Page 23 - 南京医科大学自然版

第45卷第7期 陈宗浩，吴 穹，陈 磊. 溶瘤病毒在乳腺癌治疗中的研究进展［J］.
2025年7月 南京医科大学学报（自然科学版），2025，45（7）：913-924 ·921 ·

［31］WU C X，LIN J K，HONG M，et al. Combinatorial control al. Oncolytic therapy with recombinant vaccinia viruses
of suicide gene expression by tissue ⁃ specific promoter targeting the interleukin⁃15 pathway elicits a synergistic
and microRNA regulation for cancer therapy［J］. Mol response［J］. Mol Ther Oncolytics，2023，29：158-168
Ther，2009，17（12）：2058-2066 ［45］GOVERNA V，BRITTOLI A，MELE V，et al. A replication
［32］YUAN M，WEBB E，LEMOINE N R，et al. CRISPR⁃Cas9 ⁃incompetent CD154/40L recombinant vaccinia virus in⁃
as a powerful tool for efficient creation of oncolytic duces direct and macrophage⁃mediated antitumor effects
viruses［J］. Viruses，2016，8（3）：72 in vitro and in vivo［J］. Oncoimmunology，2019，8（5）：
［33］TERADA K，WAKIMOTO H，TYMINSKI E，et al. Devel⁃ e1568162
opment of a rapid method to generate multiple oncolytic ［46］DENG L L，FAN J，DING Y D，et al. Target therapy with
HSV vectors and their in vivo evaluation using syngeneic vaccinia virus harboring IL⁃24 for human breast cancer［J］.
mouse tumor models［J］. Gene Ther，2006，13（8）：705-714 J Cancer，2020，11（5）：1017-1026
［34］TORRES⁃DOMÍNGUEZ L E，DE⁃MATOS A L，RAHMAN ［47］姚梦玮，李玉迁，徐庆胜，等. 基于蛋白质组学技术探讨
M M，et al. Methods for the construction of recombinant 麻疹减毒活疫苗191株抑制三阴性乳腺癌细胞增殖的
oncolytic myxoma viruses［J］. Methods Mol Biol，2021， 可能机制［J］. 中国肿瘤生物治疗杂志，2023，30（7）：

2225：63-75 568-576
［35］KRETSCHMER P J，JIN F，CHARTIER C，et al. Develop⁃ YAO M W，LI Y Q，XU S Q，et al. Exploring the possible
ment of a transposon⁃based approach for identifying novel mechanisms of measles attenuated live vaccine strain 191
transgene insertion sites within the replicating adenovi⁃ in inhibiting the proliferation of triple⁃negative breast can⁃
rus［J］. Mol Ther，2005，12（1）：118-127 cer cells based on proteomics technology［J］. Journal of
［36］HOWELLS A，MARELLI G，LEMOINE N R，et al. Onco⁃ Cancer Biotherapy，2023，30（7）：568-576
lytic viruses⁃interaction of virus and tumor cells in the bat⁃ ［48］FUJIYUKI T，AMAGAI Y，SHOJI K，et al. Recombinant
tle to eliminate cancer［J］. Front Oncol，2017，7：195 SLAMblind measles virus is a promising candidate for
［37］HUA X S，XUAN S Y，TANG Y Y，et al. Progression of nectin⁃4⁃positive triple negative breast cancer therapy［J］.
oncolytic virus in liver cancer treatment［J］. Front Oncol， Mol Ther Oncolytics，2020，19：127-135
2024，14：1446085 ［49］NIAVARANI S R，LAWSON C，BOUDAUD M，et al. On⁃
［38］BASSANI B，BACI D，GALLAZZI M，et al. Natural killer colytic vesicular stomatitis virus ⁃ based cellular vaccine
cells as key players of tumor progression and angiogene⁃ improves triple ⁃ negative breast cancer outcome by en⁃
+
sis：old and novel tools to divert their pro⁃tumor activities hancing natural killer and CD8 T⁃cell functionality［J］. J
into potent anti⁃tumor effects［J］. Cancers（Basel），2019， Immunother Cancer，2020，8（1）：e000465
11（4）：461 ［50］ CHEN X Y，LIU Y，ZHU W B，et al. Arming oncolytic
［39］LAWLER S E，SPERANZA M C，CHO C F，et al. Oncolytic M1 virus with gasdermin E enhances antitumor efficacy
viruses in cancer treatment：a review［J］. JAMA Oncol， in breast cancer［J］. iScience，2024，27（11）：111148
2017，3（6）：841-849 ［51］ROBERT S，ROMAN⁃ORTIZ N I，LAROCCA C J，et al.
［40］JIN S Y，WANG Q，WU H，et al. Oncolytic viruses for tri⁃ Oncolytic adenovirus for the targeting of paclitaxel⁃resis⁃
ple negative breast cancer and beyond［J］. Biomark Res， tant breast cancer stem cells［J］. Viruses，2024，16（4）：567
2021，9（1）：71 ［52］RODRÍGUEZ M D C R，RODRÍGUEZ I G，NATTRESS
［41］GHOUSE S M，NGUYEN H M，BOMMAREDDY P K，et C，et al. HDAC inhibitors enhance efficacy of the oncolyt⁃
al. Oncolytic herpes simplex virus encoding IL12 controls ic adenoviruses adΔΔ and ad⁃3Δ⁃A20T in pancreatic and
triple ⁃ negative breast cancer growth and metastasis［J］. triple⁃negative breast cancer models［J］. Viruses，2022，
Front Oncol，2020，10：384 14（5）：1006
［42］ZHAO H Q，WANG H，KONG F X，et al. Oncolytic ade⁃ ［53］NAVEED M，BATOOL Z，AZIZ T，et al. An in silico ap⁃
novirus rAd. DCN inhibits breast tumor growth and lung proach uncovering the competency of oncolytic human ad⁃
metastasis in an immune⁃competent orthotopic xenograft enovirus 52 for targeted breast cancer virotherapy［J］. Sci
model［J］. Hum Gene Ther，2019，30（2）：197-210 Rep，2024，14（1）：26405
［43］YAN Y，XU H，WANG J D，et al. Inhibition of breast can⁃ ［54］LIU K，KONG L K，CUI H W，et al. Thymosin α1 revers⁃
cer cells by targeting E2F⁃1 gene and expressing IL15 on⁃ es oncolytic adenovirus⁃induced M2 polarization of macro⁃
colytic adenovirus［J］. Biosci Rep，2019，39（7）： phages to improve antitumor immunity and therapeutic ef⁃
BSR20190384 ficacy［J］. Cell Rep Med，2024，5（10）：101751
［44］SHAKIBA Y，VOROBYEV P O，YUSUBALIEVA G M，et ［55］ANG L，LI J，DONG H，et al. Chimeric oncolytic adenovi⁃